1zv0: Difference between revisions
No edit summary |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
==MOLECULAR MODEL OF A COMPLEX BETWEEN [SAR1, BPA8]ANGII AND HAT1 RECEPTOR== | ==MOLECULAR MODEL OF A COMPLEX BETWEEN [SAR1, BPA8]ANGII AND HAT1 RECEPTOR== | ||
<StructureSection load='1zv0' size='340' side='right' caption='[[1zv0]]' scene=''> | <StructureSection load='1zv0' size='340' side='right'caption='[[1zv0]]' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>For a <b>guided tour on the structure components</b> use [ | <table><tr><td colspan='2'>For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=1ZV0 FirstGlance]. <br> | ||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | </td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=1zv0 FirstGlance], [https://www.ebi.ac.uk/pdbsum/1zv0 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=1zv0 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
<div style="background-color:#fffaf0;"> | <div style="background-color:#fffaf0;"> | ||
| Line 21: | Line 21: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Theoretical Model]] | [[Category: Theoretical Model]] | ||
[[Category: Large Structures]] | |||
[[Category: Beaulieu, M E]] | [[Category: Beaulieu, M E]] | ||
[[Category: Chamberland, C]] | [[Category: Chamberland, C]] | ||
Latest revision as of 11:25, 10 November 2021
 |
MOLECULAR MODEL OF A COMPLEX BETWEEN [SAR1, BPA8]ANGII AND HAT1 RECEPTORMOLECULAR MODEL OF A COMPLEX BETWEEN [SAR1, BPA8]ANGII AND HAT1 RECEPTOR
Structural highlights
Publication Abstract from PubMedThe peptide hormone angiotensin II (AngII) binds to the AT0 (angiotensin type 1) receptor within the transmembrane domains in an extended conformation, and its C-terminal residue interacts with transmembrane domain VII at Phe-293/Asn-294. The molecular environment of this binding pocket remains to be elucidated. The preferential binding of benzophenone photolabels to methionine residues in the target structure has enabled us to design an experimental approach called the methionine proximity assay, which is based on systematic mutagenesis and photolabeling to determine the molecular environment of this binding pocket. A series of 44 transmembrane domain III, VI, and VII X --> Met mutants photolabeled either with 125I-[Sar1,p'-benzoyl-L-Phe8]AngII or with 125I-[Sar1,p-methoxy-p'-benzoyl-L-Phe8]AngII were purified and digested with cyanogen bromide. Several mutants produced digestion patterns different from that observed with wild type human AT1, indicating that they had a new receptor contact with position 8 of AngII. The following residues form this binding pocket: L112M and Y113M in transmembrane domain (TMD) III; F249M, W253M, H256M, and T260M in TMD VI; and F293M, N294M, N295M, C296M, and L297M in TMD VII. Homology modeling and incorporation of these contacts allowed us to develop an evidence-based molecular model of interactions with human AT1 that is very similar to the rhodopsin-retinal interaction. Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay.,Clement M, Martin SS, Beaulieu ME, Chamberland C, Lavigne P, Leduc R, Guillemette G, Escher E J Biol Chem. 2005 Jul 22;280(29):27121-9. Epub 2005 May 12. PMID:15890659[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||